N/A Completed N=44 Randomized Treatment

Development/Testing of SUMMIT: a Tool to Help Patients Manage Pain While Tapering Opioids

Source: ClinicalTrials.gov NCT04746833 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Sep 2025

Primary outcomePrimary: Daily Morphine Milligram Equivalents (MME) — 25.1; 21.9 Morphine milligram equivalents per day — p=.91

Summary

There are nearly one million veterans being treated with long-term opioid therapy (LTOT) for chronic pain. Numerous short and long-term harms associated with LTOT and mounting evidence suggest they have modest or no benefit. Yet, currently available resources to support veterans to taper are inadequate. Primary care, where most LTOT in VHA is prescribed, is overburdened and straining to meet the challenge of caring for patients with chronic pain. A scalable, relatively inexpensive tapering intervention to support primary care and/or to extend the reach of resource-intensive specialty clinics would be of great benefit to veterans who are not deriving sufficient benefit from LTOT. As such, the goal of this study is to develop and test an interactive, theory-informed, multi-component mobile website to enable veterans to safely taper opioids while managing their pain.

Outcome Measures

Outcome	Result	p-value
PRIMARY Daily Morphine Milligram Equivalents (MME)	25.1; 21.9	.91
PRIMARY Minutes of Summit App Use	20.9	—
SECONDARY Behavior Intervention Rating Scale (BIRS)	4.4; 4.5	.50

Eligibility Criteria

Inclusion Criteria

Inclusion criteria for Veterans will be primary care patients who are dispensed 84 consecutive days of a stable dose of opioids (reflecting three consecutive 28-day prescriptions) through primary care and who report stable levels of pain intensity over the past month.

Exclusion Criteria

Exclusion criteria will be Veterans on liquid methadone or buprenorphine for opioid use disorder (OUD) and those who have transitioned to buprenorphine (transdermal or sublingual) for chronic pain, have hearing or visual impairments (not corrected with hearing aids or glasses), psychiatric conditions, cognitive impairments, or participating in a concurrent pain or opioid-related research study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04746833). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.